Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tiny heart vessel problems predict major cardiac events?

NCT ID NCT07293338

Knowledge-focused Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how problems in the heart's tiny blood vessels (coronary microvascular dysfunction) affect long-term outcomes in people with dilated cardiomyopathy, a condition where the heart muscle is enlarged and weak. Researchers will follow 330 participants who have already had a heart catheterization to check for blocked arteries. The goal is to see if microvascular dysfunction is linked to serious events like heart failure hospitalization, heart transplant, or death.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better predict heart complications in people with dilated cardiomyopathy, leading to more personalized monitoring and treatment.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve patient outcomes. Results may not apply to all patients with dilated cardiomyopathy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 330 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged ≥ 18 years with angiography-confirmed absence of coronary stenosis and a definitive diagnosis of dilated cardiomyopathy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Dilated cardiomyopathy comfirmed by echocardiography: LVDd \> 55 mm in men or \> 50 mm in women. * Clinically evident congestive heart failure: Compatible symptoms and signs, and BNP ≥ 35 pg/mL or NT-proBNP ≥ 125 pg/mL, and LV systolic dysfunction defined by LVEF \< 45 %. * Coronary angiography showing stenosis ≤ 50 % in all major epicardial vessels. Exclusion Criteria: * Patients with coronary artery disease, hypertensive heart disease, rheumatic valvular heart disease, myocarditis, and other secondary cardiomyopathies. * poor angiographic image quality

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dilated cardiomyopathy (DCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dilated cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dilated cardiomyopathy (DCM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The second affiliated hospital of Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.